# CRBU — slm-full-cpu

## Metadata

ticker: CRBU
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: ccbf3164569e016074c1512eb77605a5c0da11d3f6ef06a657d51b6d5e4517d5
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 605, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 194.409, "latency_s_total": 194.409, "parse_failure": 0, "prompt_tokens": 3132, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 528, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 169.38, "latency_s_total": 169.38, "parse_failure": 0, "prompt_tokens": 3121, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 141, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 59.728, "latency_s_total": 59.728, "parse_failure": 0, "prompt_tokens": 666, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 142, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 75.956, "latency_s_total": 75.956, "parse_failure": 0, "prompt_tokens": 660, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 215, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 89.955, "latency_s_total": 89.955, "parse_failure": 0, "prompt_tokens": 604, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 155, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 81.686, "latency_s_total": 81.686, "parse_failure": 0, "prompt_tokens": 689, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 954, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 112.55, "latency_s_total": 112.55, "parse_failure": 0, "prompt_tokens": 1692, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "CRBU",
  "company_name": "Caribou Biosciences, Inc.",
  "current_price": 1.19,
  "currency": "USD",
  "market_cap": 127576944.0,
  "forward_pe": -0.94195503,
  "week_52_high": 3.535,
  "week_52_low": 1.17,
  "financial_currency": "USD",
  "revenue": 10035000.0,
  "net_income": -103403000.0,
  "profit_margin_pct": 0.0,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-05",
    "summary": "Item 1A. Risk Factors. Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Annual Report on Form 10-K, including our financial statements and related notes, before making an investment decision. These disclosures reflect our beliefs and opinions as to factors that could materially and adversely affect our company and its securities in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not such factors have occurred in the past or their likelihood of occurring in the future. Furthermore, the risks described below are not the only ones faci"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-13",
    "summary": "Item 1A. Risk Factors. There have been no material changes to the Risk Factors previously disclosed in Item 1A. to Part I of our Form 10-K. The risks described in our Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities. Unregistered Sales of Equity Securities during the Three Months Ended June 30, 2026 There were no unregistered sales of equity securities during the three months ended June 30, 2026. Item 5. Other Information. During the quarter ended June 30, 2026, none of our directo"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided risk factors from the Annual Report on Form 10-K for ticker CRBU, here are the key takeaways regarding the company's financial position and operational outlook:

**Financial Performance and Losses**
*   **Significant Operating Losses:** The company has incurred significant operating losses every year since its inception. For the years ended December 31, 2025, and 2024, net losses were $148.1 million and $149.1 million, respectively.
*   **Accumulated Deficit:** As of December 31, 2025, the company had an accumulated deficit of $596.5 million.
*   **No Revenue:** The company has not commercialized any products and has never generated revenue from product sales, having devoted almost all financial resources to research and development.

**Capital Requirements and Liquidity**
*   **Need for Additional Financing:** The company requires substantial additional capital to conduct its planned pivotal clinical trial for vispa-cel and to implement operating plans for its product candidates, vispa-cel and CB-011.
*   **Current Cash Position:** As of December 31, 2025, the company held $142.8 million in cash, cash equivalents, and marketable securities. This is expected to fund current operations for at least the next 12 months, though this assumption may prove incorrect, and resources could be depleted sooner.
*   **Risk of Insufficient Funds:** The company currently does not have sufficient funds to conduct the planned pivotal clinical trial for vispa-cel. Failure to obtain additional financing would prevent the completion of development and commercialization for vispa-cel and CB-011.

**Operational Risks and Expenses**
*   **Increasing Costs:** Expenses are expected to increase substantially as the company progresses clinical trials (particularly the pivotal trial for vispa-cel), hires employees, expands manufacturing capabilities, seeks regulatory approvals, and establishes commercialization infrastructure.
*   **Unpredictability:** The company cannot predict the extent of future losses or when it will become profitable, if at all. Even if profitable, sustaining or increasing profitability is not guaranteed.
*   **External Factors:** Capital requirements may increase significantly due to clinical trial results, regulatory delays, pandemics, litigation costs, patent maintenance, and the need to establish sales and marketing infrastructure.

**Product Development Status**
*   **Product Candidates:** The company is focused on vispa-cel and CB-011. If vispa-cel advances to the planned pivotal clinical trial, the company will incur significant expenses for a large, multicenter trial in the U.S. and foreign jurisdictions.
*   **Commercialization Challenges:** If marketing approval is obtained, the company expects to incur significant commercialization expenses unless commercialization partners are secured to bear these costs.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Additional Capital:** The company has incurred significant operating losses since inception, with net losses of $148.1 million in 2025 and $149.1 million in 2024, resulting in an accumulated deficit of $596.5 million as of December 31, 2025. The company has never generated revenue from product sales and anticipates continued operating losses for the foreseeable future.
*   **Inability to Achieve Profitability:** The company is unable to predict when it will become profitable, if at all, and may not be able to sustain or increase profitability even if it does become profitable.
*   **Insufficient Funds for Clinical Trials:** As of December 31, 2025, the company had $142.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next 12 months. However, the company currently does not have sufficient funds to conduct its planned pivotal clinical trial for vispa-cel. Failure to obtain additional financing would prevent the completion of development and commercialization for vispa-cel and/or CB-011.
*   **High Costs of Development and Commercialization:** Costs increase substantially as product candidates advance through clinical phases with greater numbers of patients. Significant expenses are expected for advancing vispa-cel into a pivotal clinical trial, expanding manufacturing capabilities, seeking regulatory approvals, and establishing sales, marketing, and distribution infrastructure.
*   **Operational and Regulatory Risks:** Risks include potential delays in clinical trials due to unforeseen events, pandemics, or regulatory environments; difficulties in receiving regulatory clearances; failure of clinical trials to meet endpoints; potential safety issues; and the need to hire additional employees or acquire in-license intellectual property.
*   **Litigation and Intellectual Property Costs:** The company faces risks related to defending against securities class action litigation, enforcing patents against third parties, or being sued for infringement, as well as costs associated with maintaining its patent portfolio and fulfilling contractual obligations to reimburse parties for patent prosecution and maintenance.
*   **Management Distraction:** Additional fundraising efforts may divert management’s attention from day-to-day activities, adversely affecting the ability to develop and commercialize product candidates.
*   **Uncertainty of Future Funding:** There is no certainty that additional funding will be available when needed, on acceptable terms, or at all. Changing circumstances may cause the company to consume capital faster than anticipated.

## Pre-written sections (judge input)

### Financial Health

Caribou Biosciences, Inc. (CRBU) is currently trading at $1.19, reflecting a market capitalization of approximately $127.6 million. The company reported revenue of $10.04 million but incurred a net loss of $103.4 million, resulting in a negative profit margin and an ineffective forward P/E ratio. This significant net loss highlights the firm's ongoing reliance on capital raises to fund its pre-revenue or early-stage biotechnology operations. While the stock is near its 52-week low, the substantial gap between revenue and net income underscores the high financial risk associated with its current development phase.

### Recent Developments

Caribou Biosciences reported a net loss of $103.4 million and minimal revenue of $10 million in its latest filings, highlighting the company's continued reliance on capital raises to fund operations. The stock is trading near its 52-week low of $1.17 at $1.19, reflecting significant investor caution amid persistent profitability challenges. With a negative forward P/E ratio and no dividend yield, the investment thesis remains heavily dependent on the successful clinical progression of its CRISPR-based pipeline rather than current financial performance. Investors should closely monitor upcoming clinical trial data and cash burn rates, as the company faces substantial execution and funding risks.

### SEC Filing Highlights
Caribou Biosciences reported net losses of $148.1 million for the year ended December 31, 2025, maintaining its history of zero revenue as it remains pre-commercialization. The company holds $142.8 million in cash and equivalents, which management estimates will fund operations for at least the next 12 months, though this timeline is subject to significant uncertainty. Critical liquidity risks persist, as current resources are insufficient to fully execute the planned pivotal clinical trial for vispa-cel without securing additional financing. Consequently, the company faces substantial capital requirements to support ongoing R&D for vispa-cel and CB-011, with expenses expected to rise sharply as trials advance.

### Risk Factors

*   **Severe Financial Constraints and Liquidity Risk:** The company has incurred significant operating losses (accumulated deficit of $596.5 million) and has never generated revenue from product sales. Current cash reserves are insufficient to fund the planned pivotal clinical trial for vispa-cel, creating a high risk that the company will be unable to complete development or commercialization without obtaining additional financing, which is not guaranteed.
*   **High Development Costs and Profitability Uncertainty:** Advancing product candidates through clinical phases involves substantially increasing costs for trials, manufacturing, and regulatory approvals. The company cannot predict when it will become profitable, if at all, and faces the risk of sustained or increased operating losses for the foreseeable future.
*   **Operational, Regulatory, and Litigation Risks:** The company faces potential delays in clinical trials due to regulatory or unforeseen events, risks of trial failures, and significant costs associated with defending against securities litigation and enforcing intellectual property rights. Additionally, fundraising efforts may distract management from core development activities.

## Audited (Exec Summary + Outlook)

### Executive Summary
Caribou Biosciences is a pre-commercialization biotechnology firm leveraging CRISPR technology to develop therapies like vispa-cel and CB-011, currently operating with minimal revenue and a substantial accumulated deficit of $596.5 million. The stock is trading near its 52-week low, reflecting significant investor caution amid persistent profitability challenges and a negative forward P/E ratio. The single most important near-term variable is the company’s ability to secure additional financing, as current cash reserves are insufficient to fully execute the planned pivotal clinical trial for vispa-cel.

### Outlook
The directional outlook for Caribou Biosciences is cautiously constructive but heavily contingent on execution and capital access. Key variables to monitor include the progress of clinical trials for vispa-cel and CB-011, as positive data could validate the CRISPR platform and attract strategic partnerships or favorable financing terms. Conversely, headwinds such as trial delays, adverse safety signals, or an inability to raise necessary capital would significantly weaken the investment thesis given the company's limited liquidity runway. The view would shift from cautious to negative if management fails to secure funding before cash reserves are depleted, while a successful pivotal trial outcome or strategic alliance would provide the catalyst needed to mitigate current liquidity concerns.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "accumulated deficit of $596.5 million"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights and RAG — Risk Factors both explicitly state "accumulated deficit of $596.5 million as of December 31, 2025," and the pre-written Risk Factors section repeats this figure.

---

CLAIM: "trading near its 52-week low"
LABEL: SUPPORTED
REASON: Current price is $1.19 and the 52-week low is $1.17; $1.19 is $0.02 above the low, confirming the stock is near its 52-week low arithmetically.

---

CLAIM: "negative forward P/E ratio"
LABEL: SUPPORTED
REASON: The source data shows forward_pe = -0.94195503, which is explicitly negative, confirming this claim.

---

CLAIM: "current cash reserves are insufficient to fully execute the planned pivotal clinical trial for vispa-cel"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly states "the company currently does not have sufficient funds to conduct the planned pivotal clinical trial for vispa-cel," and the pre-written SEC Filing Highlights section repeats this directly.

---

**OUTLOOK**

---

CLAIM: "progress of clinical trials for vispa-cel and CB-011"
LABEL: SUPPORTED
REASON: Both vispa-cel and CB-011 are explicitly named as the company's product candidates in the RAG — SEC Highlights and Risk Factors sections.

---

CLAIM: "positive data could validate the CRISPR platform and attract strategic partnerships or favorable financing terms"
LABEL: INFERENCE
REASON: The source data confirms CRISPR technology and the need for financing/partnerships, and this is a standard directional inference from those facts; no specific partnership figure or financing term is cited.

---

CLAIM: "company's limited liquidity runway"
LABEL: SUPPORTED
REASON: The source data states $142.8 million in cash funds operations for "at least the next 12 months," and explicitly notes funds are insufficient for the pivotal trial, supporting the characterization of a limited liquidity runway.

---

CLAIM: "management fails to secure funding before cash reserves are depleted"
LABEL: INFERENCE
REASON: This is a forward-looking conditional derived directly from the source data's explicit statement that current funds are insufficient for the pivotal trial and that failure to obtain financing would prevent completion of development — no specific depletion date or threshold figure is introduced beyond what the source supports.

---

**SUMMARY NOTE:** No unsupported claims were identified. The Executive Summary and Outlook contain no fabricated figures, invented price targets, or metrics absent from the source data. All quantitative figures ($596.5 million deficit, $1.19 price, 52-week low proximity, negative forward P/E, vispa-cel/CB-011 pipeline references, and liquidity insufficiency) are directly traceable to the source. The two INFERENCE labels reflect directional extrapolations that are fully derivable from present source facts without introducing any absent data.
